Your browser doesn't support javascript.
Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
Su, Qiu-Dong; Zou, Ye-Ning; Yi, Yao; Shen, Li-Ping; Ye, Xiang-Zhong; Zhang, Yang; Wang, Hui; Ke, Hong; Song, Jing-Dong; Hu, Ke-Ping; Cheng, Bo-Lin; Qiu, Feng; Yu, Peng-Cheng; Zhou, Wen-Ting; Zhao, Ran; Cao, Lei; Dong, Gao-Feng; Bi, Sheng-Li; Wu, Gui-Zhen; Gao, George Fu; Zheng, Jerry.
  • Su QD; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Zou YN; Sinovac Biotech Co., Ltd, Beijing 100085, China.
  • Yi Y; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Shen LP; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Ye XZ; Beijing WanTai Biological Pharmacy Enterprise Co., Ltd, Beijing 102206, China.
  • Zhang Y; Artron Bioresearch Inc., Burnaby, BC V5A1M6, Canada.
  • Wang H; Artron Bioresearch Inc., Burnaby, BC V5A1M6, Canada.
  • Ke H; Artron Bioresearch Inc., Burnaby, BC V5A1M6, Canada.
  • Song JD; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Hu KP; Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100193, China.
  • Cheng BL; Jianxuan Business Center, Tianjin 300110, China.
  • Qiu F; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Yu PC; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Zhou WT; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Zhao R; Sinovac Biotech Co., Ltd, Beijing 100085, China.
  • Cao L; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Dong GF; Sinovac Life Sciences Co., Ltd, Beijing 100085, China.
  • Bi SL; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China. Electronic address: bisl@ivdc.chinacdc.cn.
  • Wu GZ; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Gao GF; National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.
  • Zheng J; Artron Bioresearch Inc., Burnaby, BC V5A1M6, Canada.
Vaccine ; 39(8): 1241-1247, 2021 02 22.
Article in English | MEDLINE | ID: covidwho-1039581
ABSTRACT
Without approved vaccines and specific treatments, COVID-19 is spreading around the world with above 26 million cases and approximately 864 thousand deaths until now. An efficacious and affordable vaccine is urgently needed. The Val308 - Gly548 of spike protein of SARS-CoV-2 linked with Gln830 - Glu843 of Tetanus toxoid (TT peptide) (designated as S1-4) and without TT peptide (designated as S1-5) were expressed and renatured. The antigenicity and immunogenicity of S1-4 were evaluated by Western Blotting (WB) in vitro and immune responses in mice, respectively. The protective efficiency was measured preliminarily by microneutralization assay (MN50). The soluble S1-4 and S1-5 protein was prepared to high homogeneity and purity. Adjuvanted with Alum, S1-4 protein stimulated a strong antibody response in immunized mice and caused a major Th2-type cellular immunity supplemented with Th1-type immunity. Furthermore, the immunized sera could protect the Vero E6 cells from SARS-CoV-2 infection with neutralizing antibody titer 256. Recombinant SARS-CoV-2 RBD with a built in T helper epitope could stimulate both strong humoral immunity supplemented with cellular immunity in mice, demonstrating that it could be a promising subunit vaccine candidate.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Epitopes, T-Lymphocyte / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / Antibodies, Viral Type of study: Experimental Studies Topics: Vaccines Limits: Animals / Female / Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2021.01.044

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Epitopes, T-Lymphocyte / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / Antibodies, Viral Type of study: Experimental Studies Topics: Vaccines Limits: Animals / Female / Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2021.01.044